OCULAR THERAPEUTIX, INC
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is an integrated biopharmaceutical company dedicated to developing and commercializing innovative therapies for ophthalmic diseases. The company's website is www.ocularrx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What OCULAR THERAPEUTIX, INC does
In the company’s own words
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is an integrated biopharmaceutical company dedicated to developing and commercializing innovative therapies for ophthalmic diseases. The company's website is www.ocularrx.com.
The company operates around a proprietary bioresorbable hydrogel-based formulation technology platform called ELUTYX, which enables sustained, programmed drug delivery to the eye. This technology has been utilized in the human body since 1992 and has demonstrated safety and effectiveness across over five million patients through eight FDA-approved treatments. Ocular Therapeutix leverages ELUTYX to develop products addressing significant unmet needs in retinal and anterior segment eye diseases.
The company's commercial product is DEXTENZA, an FDA-approved drug-eluting intracanalicular insert for treating ocular inflammation and pain following ophthalmic surgery and for ocular itching associated with allergic conjunctivitis. DEXTENZA has been used in nearly 750,000 eyes since launch with a favorable safety profile. The company's lead clinical asset is AXPAXLI, an investigational axitinib intravitreal hydrogel currently in Phase 3 registrational trials for wet age-related macular degeneration and diabetic retinal disease. AXPAXLI is designed to provide sustained drug delivery over six to twelve months, potentially reducing treatment burden compared to frequent injections required by current standard-of-care therapies.
Ocular Therapeutix also has OTX-TIC, a travoprost intracameral hydrogel that completed Phase 2 testing for open-angle glaucoma and ocular hypertension, with the company currently evaluating next steps for this program.
The company maintains a single manufacturing facility for DEXTENZA and a separate facility for clinical trial materials and research activities. Ocular Therapeutix has entered into a collaboration agreement with AffaMed Therapeutics Limited for development and commercialization of DEXTENZA and OTX-TIC in select Asian markets. The company targets the exudative retinal diseases market, estimated to include up to 8.3 million patients in the United States by 2030 and representing approximately 9.4 billion dollars in annual U.S. revenues.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BEDFORD, MA
- Fiscal year end
- December
- CIK
- 1393434
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns OCULAR THERAPEUTIX, INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · OCULAR THERAPEUTIX, INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do OCULAR THERAPEUTIX, INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of OCULAR THERAPEUTIX, INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in OCULAR THERAPEUTIX, INC's last four quarterly filings that the numbers alone won't show?”